|
Gene: SPATS2 |
Gene summary for SPATS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPATS2 | Gene ID | 65244 |
Gene name | spermatogenesis associated serine rich 2 | |
Gene Alias | Nbla00526 | |
Cytomap | 12q13.12 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R101 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
65244 | SPATS2 | GSM5276937 | Human | Endometrium | EEC | 3.25e-04 | -2.17e-01 | -0.0897 |
65244 | SPATS2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.04e-20 | -1.92e-02 | -0.1869 |
65244 | SPATS2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.16e-20 | -2.02e-01 | -0.1875 |
65244 | SPATS2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.43e-21 | -1.50e-01 | -0.1883 |
65244 | SPATS2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 6.94e-21 | -8.71e-02 | -0.1934 |
65244 | SPATS2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.62e-31 | -1.32e-01 | -0.1917 |
65244 | SPATS2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.22e-31 | -1.45e-01 | -0.1916 |
65244 | SPATS2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 4.09e-03 | -1.02e-01 | -0.1269 |
65244 | SPATS2 | LZE4T | Human | Esophagus | ESCC | 1.20e-09 | 3.01e-01 | 0.0811 |
65244 | SPATS2 | LZE7T | Human | Esophagus | ESCC | 9.23e-05 | 4.67e-01 | 0.0667 |
65244 | SPATS2 | LZE8T | Human | Esophagus | ESCC | 5.56e-11 | 2.50e-01 | 0.067 |
65244 | SPATS2 | LZE20T | Human | Esophagus | ESCC | 3.27e-04 | 1.00e-01 | 0.0662 |
65244 | SPATS2 | LZE22T | Human | Esophagus | ESCC | 8.07e-05 | 3.69e-01 | 0.068 |
65244 | SPATS2 | LZE24T | Human | Esophagus | ESCC | 2.71e-12 | 3.24e-01 | 0.0596 |
65244 | SPATS2 | LZE6T | Human | Esophagus | ESCC | 3.47e-03 | 1.07e-01 | 0.0845 |
65244 | SPATS2 | P2T-E | Human | Esophagus | ESCC | 7.07e-78 | 1.43e+00 | 0.1177 |
65244 | SPATS2 | P4T-E | Human | Esophagus | ESCC | 7.43e-29 | 7.86e-01 | 0.1323 |
65244 | SPATS2 | P5T-E | Human | Esophagus | ESCC | 2.59e-03 | 4.61e-02 | 0.1327 |
65244 | SPATS2 | P8T-E | Human | Esophagus | ESCC | 2.12e-25 | 4.06e-01 | 0.0889 |
65244 | SPATS2 | P9T-E | Human | Esophagus | ESCC | 2.23e-09 | 1.87e-01 | 0.1131 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPATS2 | SNV | Missense_Mutation | rs781041192 | c.1265N>T | p.Pro422Leu | p.P422L | Q86XZ4 | protein_coding | deleterious(0.03) | benign(0.166) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
SPATS2 | SNV | Missense_Mutation | c.229G>T | p.Val77Leu | p.V77L | Q86XZ4 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
SPATS2 | deletion | Frame_Shift_Del | novel | c.565delN | p.Lys189SerfsTer3 | p.K189Sfs*3 | Q86XZ4 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SPATS2 | deletion | Frame_Shift_Del | novel | c.663delN | p.Met223TrpfsTer12 | p.M223Wfs*12 | Q86XZ4 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SPATS2 | SNV | Missense_Mutation | c.371N>T | p.Ser124Leu | p.S124L | Q86XZ4 | protein_coding | tolerated(0.17) | benign(0.01) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPATS2 | SNV | Missense_Mutation | c.1480N>G | p.Gln494Glu | p.Q494E | Q86XZ4 | protein_coding | tolerated(0.09) | benign(0.107) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPATS2 | SNV | Missense_Mutation | rs769173005 | c.767N>A | p.Arg256Gln | p.R256Q | Q86XZ4 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SPATS2 | SNV | Missense_Mutation | c.1423N>T | p.Arg475Cys | p.R475C | Q86XZ4 | protein_coding | deleterious(0.01) | possibly_damaging(0.609) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPATS2 | SNV | Missense_Mutation | novel | c.263N>C | p.Lys88Thr | p.K88T | Q86XZ4 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AA-3855-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SPATS2 | SNV | Missense_Mutation | c.314N>A | p.Gly105Asp | p.G105D | Q86XZ4 | protein_coding | tolerated(0.33) | benign(0.061) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |